You already know smoking is bad for you. The questions worth answering are narrower: what does quitting give back, on what timescale, and is there an age at which it stops being worth doing? Plus vaping, where the honest answer is one almost nobody gives.
Smoking is one of the fourteen modifiable risk factors named by the Lancet Commission on dementia prevention — we've covered what its headline 45% figure does and doesn't mean. This piece is about the recovery curve.
What is established, and what is inferred
The vascular mechanism is the solid one. Cigarette smoke reduces the bioavailability of nitric oxide in the endothelium — the cell layer lining every blood vessel you have — and from there the sequence is well mapped: endothelial dysfunction, platelets and macrophages sticking where they should not, a procoagulant inflammatory local environment, and macrophages loading up on oxidised lipoproteins to become foam cells in an early plaque.
It is a brain mechanism because the arteries are the same. What damages the vessels feeding the heart damages those feeding the brain, which is why smoking also sits among the ten factors behind roughly 90% of population-attributable stroke risk.
There is imaging evidence too: in 504 people from the Lothian Birth Cohort 1936, scanned at 73, pack-years showed a diffuse dose-dependent negative association with cortical thickness, and some of those associations survived adjustment for childhood cognitive ability measured before anyone started smoking — weakening the reverse explanation that thinner cortices lead to smoking.
Now the part that gets hand-waved. Oxidative stress and inflammation are genuinely elevated in smokers and genuinely part of that sequence. But the chain from one person's oxidative load to their memory score has not been measured in humans; it is inferred from biochemistry and animal work, and the standard mechanistic review says plainly that great gaps remain. Writing "oxidative stress damages your neurons" as an observed human finding is filling a gap with confident prose.
Two honesty notes. The literature was actively muddied: across 43 studies, a quarter had tobacco-industry-affiliated authors, and affiliation predicted the answer. Independent cohort studies pooled to a relative risk of Alzheimer's of 1.45 (95% CI 1.16–1.80); the three industry-affiliated cohorts pooled to a non-significant 0.60 (0.27–1.32). The "smoking protects against Alzheimer's" line was substantially manufactured. Survivor bias runs the other way: smokers die earlier — roughly double the hazard of death in one midlife cohort — so studies of dementia in the old are studies of those who survived smoking.
The nicotine question, handled carefully
Nicotine binds nicotinic acetylcholine receptors and facilitates release of noradrenaline and acetylcholine, the transmitters most associated with vigilance, so there is real reason to expect acute attentional effects. A meta-analysis of 41 double-blind, placebo-controlled studies found significant positive effects on six of the nine domains it could pool, including alerting attention, with effect sizes of 0.16 to 0.44 — small. Its studies used non-smokers, or smokers deprived two hours at most, which is what lets the authors argue enhancement rather than withdrawal relief.
Then the trials. A 2012 pilot randomised 74 non-smoking people with amnestic mild cognitive impairment to a 15mg/day nicotine patch or placebo for six months. It had more than one primary outcome and they disagreed: the attention measure improved significantly, the clinician's global impression of change did not. Whether any of it mattered clinically, the authors wrote, needed larger studies.
This is the part that rarely gets reported. The MIND trial ran 348 people with mild cognitive impairment for two years on a 21mg patch or placebo. On the primary outcome — total immediate recall on a word-list test — the difference was 0.367 points favouring nicotine, 95% CI −0.783 to 1.516, p=0.530. Null. The clinical global impression secondary came out at p=0.187, and every secondary interval crosses zero. Retention was poor — 91 of 171 on nicotine and 106 of 177 on placebo completed — which weakens the power without turning a null into a finding. Small acute effects on lab tasks, then a negative two-year trial. That is not a nootropic.
The confound deserves stating, because the industry relies on it. A 2024 crossover study run by British American Tobacco's R&D group took 40 smokers, imposed twelve hours of nicotine abstinence, then had them use a cigarette or a nicotine e-cigarette, and reported improved sustained attention versus no product. That design measures relief of a deficit the product itself created. Withdrawal reliably impairs sustained attention, working memory and response inhibition, and dependence severity is indexed by how soon after waking someone needs the first cigarette — because that tracks overnight withdrawal. The focus boost a smoker feels is mostly a return to their own baseline, not a rise above a non-smoker's.
Cessation: what comes back, and when
The most useful recent study matched 4,718 people who quit against 4,718 continuing smokers across three cohorts in twelve countries, aged 40 to 89. In the six years before quitting, the groups declined at indistinguishable rates — which is what makes the rest credible. After, quitters declined more slowly: memory by 0.05 SDs (95% CI 0.00–0.10, p=0.036), fluency by 0.05 SDs (0.01–0.10, p=0.030). The memory interval touches zero; small and borderline, not a transformation. The finding that matters most is the one that wasn't there: no interaction with age at cessation. Quitting at 75 bent the curve as much as quitting at 45.
Longer-horizon convergence: in Whitehall II, male current smokers declined faster than never-smokers over ten years (global cognition difference −0.09, 95% CI −0.15 to −0.03). Recent ex-smokers were still declining faster on executive function; ex-smokers of ten years or more were indistinguishable from never-smokers. In women, decline did not vary by smoking status at all — an unexplained null worth reporting. And no cohort can fully separate quitting from the habits travelling with it: smoking and heavy drinking cluster in the same people, and in Whitehall II the combination declined faster than either alone.
For diagnoses rather than test scores, a Korean cohort of 46,140 men aged 60 and over found quitters of four years or more at lower dementia risk than continual smokers (HR 0.86, 95% CI 0.75–0.99), never-smokers 0.81 (0.71–0.91). Quitters of under four years did not differ significantly: the benefit takes time to appear. For Alzheimer's only never-smokers reached significance; for vascular dementia long-term quitters did (0.68, 0.48–0.96).
Structure is slowest. In those same Lothian data, the cortex appeared to partially recover for each year without cigarettes — but at that sample's average pack-years, full recovery of affected regions was estimated at around 25 years. It rests on a single scan with recalled histories rather than repeated imaging, so treat it as an order of magnitude: partial recovery starts immediately, complete recovery on a timescale most people will not finish.
Sleep is the fastest thing to change
Nicotine has an average half-life of about two hours. In a regular smoker, levels climb over four to six hours, plateau across the day and fall overnight — so the brain gets nicotine round the clock, and withdrawal in the small hours.
Polysomnography on 6,400 Sleep Heart Health Study participants found current smokers took 5.4 minutes longer than never-smokers to fall asleep (95% CI 2.9–7.9), slept 14.0 minutes less (6.4–21.7), and had a relative increase in light stage 1 sleep of 1.24 (1.14–1.33) with a relative decrease in slow-wave sleep of 0.86 (0.78–0.95) — the opposite of what anyone chasing deep sleep wants.
Former smokers showed no difference from never-smokers at all. The authors read it as nicotine and acute withdrawal both contributing. If you smoke and wake at 3am, nocturnal withdrawal is plausibly part of it — the logic by which a stimulant taken too late fragments the night, except this one is dosed until bedtime by design.
Vaping: the honest answer is that nobody knows
There is no long-term cognitive outcome data on vaping. Not "the evidence is mixed" — it does not exist. The oldest e-cigarette users have not been followed long enough for late-life cognitive trajectories to be observable, and the Cochrane living review does not list cognition among its outcomes. Its safety conclusion: no serious short-term harm detected, longer and larger trials needed.
What fills the gap is not cognitive outcome data. The most-cited study surveyed 18,535 US adolescents; ever-vapers more often reported "serious difficulty concentrating, remembering, or making decisions because of a physical, mental, or emotional condition" (adjusted OR 3.13, 95% CI 2.25–4.34). That is a self-reported disability screening item, not a cognitive test, measured once, in an age group where those likeliest to vape are also likeliest to have the conditions it names. It cannot say which came first. The rest of the gap is industry abstinence-relief studies of the kind above.
What is established is narrower: nicotine e-cigarettes produce higher quit rates than nicotine replacement therapy (RR 1.61, 95% CI 1.23–2.12; 11 studies, 4,114 participants; high-certainty evidence). For a smoker the relevant comparison is not vaping against nothing but vaping against continuing to smoke — a different claim from "vaping is cognitively harmless," which nobody can make yet.
We sell nothing that helps with this
Nothing in our range helps anyone quit smoking, and nothing in anyone's does either: no supplement has credible evidence for cessation, or for repairing the damage above. The only thing that reverses it is not smoking, over years — so our advice here is a GP appointment, which is the bar we try to hold ourselves to and the same reason we say plainly that exercise beats anything in a capsule.
The best-evidenced treatments are combination nicotine replacement therapy and varenicline first-line, bupropion second-line on lower quit rates, and behavioural support alongside medication rather than instead of it. Which suits an individual is a conversation with a GP or stop-smoking service, not something a supplement company should advise on. What works in addiction treatment generally is here.
And no lecture. If you smoke you have heard the lecture; what you may not have heard is that the curve bends within about six years, that it bends at 75 about as much as at 45, that sleep comes back fastest, and that the cortex takes decades.
This article is information, not medical advice, and it cannot assess anyone's individual risk. Smoking cessation medications have contraindications and interactions; decisions about them belong with a doctor or a stop-smoking service. Our supplements are not intended to diagnose, treat, cure or prevent any disease.
Sources: Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572–628. doi:10.1016/S0140-6736(24)01296-0 · Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34:509–515. doi:10.1161/ATVBAHA.113.300156 · Karama S, Ducharme S, Corley J, et al. Cigarette smoking and thinning of the brain's cortex. Mol Psychiatry. 2015;20:778–785. doi:10.1038/mp.2014.187 · Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis. 2010;19:465–480. doi:10.3233/JAD-2010-1240 · Sabia S, Marmot M, Dufouil C, Singh-Manoux A. Smoking history and cognitive function in middle age from the Whitehall II study. Arch Intern Med. 2008;168:1165–1173. doi:10.1001/archinte.168.11.1165 · Prochaska JJ, Benowitz NL. Current advances in research in treatment and recovery: nicotine addiction. Sci Adv. 2019;5:eaay9763. doi:10.1126/sciadv.aay9763 · Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210:453–469. doi:10.1007/s00213-010-1848-1 · Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78:91–101. doi:10.1212/WNL.0b013e31823efcbb · Memory Improvement Through Nicotine Dosing (MIND) Study, NCT02720445 — posted trial results, US National Library of Medicine. clinicaltrials.gov/study/NCT02720445 · Ashare RL, Falcone M, Lerman C. Cognitive function during nicotine withdrawal: implications for nicotine dependence treatment. Neuropharmacology. 2014;76 Pt B:581–591. doi:10.1016/j.neuropharm.2013.04.034 · Green HJ, O'Shea OK, Cotter J, Philpott HL, Newland N. An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence. Harm Reduct J. 2024;21:78. doi:10.1186/s12954-024-00993-0 · Bloomberg M, Brown J, Di Gessa G, Bu F, Steptoe A. Cognitive decline before and after mid-to-late-life smoking cessation: a longitudinal analysis of prospective cohort studies from 12 countries. Lancet Healthy Longev. 2025;6:100753. doi:10.1016/j.lanhl.2025.100753 · Sabia S, Elbaz A, Dugravot A, et al. Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study. Arch Gen Psychiatry. 2012;69:627–635. doi:10.1001/archgenpsychiatry.2011.2016 · Hagger-Johnson G, Sabia S, Brunner EJ, et al. Combined impact of smoking and heavy alcohol use on cognitive decline in early old age: Whitehall II prospective cohort study. Br J Psychiatry. 2013;203:120–125. doi:10.1192/bjp.bp.112.122960 · Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: a longitudinal study. Ann Clin Transl Neurol. 2018;5:1192–1199. doi:10.1002/acn3.633 · Zhang L, Samet J, Caffo B, Punjabi NM. Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol. 2006;164:529–537. doi:10.1093/aje/kwj231 · Xie C, Xie Z, Li D. Association of electronic cigarette use with self-reported difficulty concentrating, remembering, or making decisions in US youth. Tob Induc Dis. 2020;18:106. doi:10.18332/tid/130925 · Lindson N, Livingstone-Banks J, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2026;8:CD010216. doi:10.1002/14651858.CD010216.pub11